ArticleInternational journal of molecular sciences2025
Enhancing Local Functional Structure Features to Improve Drug-Target Interaction Prediction.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Artificial Intelligence in Nephrology-State of the Art on Theoretical Background, Molecular Applications, and Clinical Interpretation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Molecular simulation is central to modern drug discovery but is often limited by high computational cost and the complexity of molecular interactions. Deep-learning drug-target interaction (DTI) prediction can accelerate screening; however, many models underuse the local functional structure features-binding motifs, reactive groups, and residue-level fragments-that drive recognition. We present LoF-DTI, a framework that explicitly represents and couples such local features. Drugs are converted from SMILES into molecular graphs and targets from sequences into feature representations. On the drug side, a Jumping Knowledge (JK) enhanced Graph Isomorphism Network (GIN) extracts atom- and neighborhood-level patterns; on the target side, residual CNN blocks with progressively enlarged receptive fields, augmented by N-mer substructural statistics, capture multi-scale local motifs. A Gated Cross-Attention (GCA) module then performs atom-to-residue interaction learning, highlighting decisive local pairs and providing token-level interpretability through attention scores. By prioritizing locality during both encoding and interaction, LoF-DTI delivers competitive results across multiple benchmarks and improves early retrieval relevant to virtual screening. Case analyses show that the model recovers known functional binding sites, suggesting strong potential to provide mechanism-aware guidance for molecular simulation and to streamline the drug design pipeline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.